Expertise in
9
conditions

Franco Aversa

Parma, IT 
Expertise in
9
conditions
Parma, IT 

Overview

Franco Aversa practices practicing medicine in Parma, Italy.

Mr. Aversa is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Multiple Myeloma, Aspergillosis, Leukemia, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 116 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Parma, Italy
Other Locations
Pavia, Italy
Udine, Italy
Catania, Italy
Rionero In Vulture, Italy
Perugia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria
Enrollment Status: Completed
Publish Date: November 25, 2022
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Enrollment Status: Completed
Publish Date: June 08, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.
Enrollment Status: Unknown
Publish Date: January 05, 2022
Intervention Type: Behavioral
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

116 Total Publications

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Journal: Nature communications
Published: February 03, 2023

Frequently Asked Questions about Franco Aversa

Is Franco Aversa a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Franco Aversa is classified as an Distinguished expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Franco Aversa participate in research or clinical trials?

Yes. Franco Aversa has published 116 articles and abstracts on conditions like Myelofibrosis. You can view a list of Franco Aversa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Aversa's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile